首页> 外国专利> Tumorspecific PET/MR(T1), PET/MR(T2) and PET/CT contrast agent

Tumorspecific PET/MR(T1), PET/MR(T2) and PET/CT contrast agent

机译:肿瘤特异性PET / MR(T1),PET / MR(T2)和PET / CT造影剂

摘要

New types of nanoparticle-based dual-modality positron emission tomography/magnetic resonance imaging (PET/MRI) and positron emission tomography/computed tomography (PET/CT) tumorspecific contrast agents have been developed. The base of the new type contrast agents is biopolymer-based nanoparticle with PET, MRI and CT active ligands. The nanoparticle contains at least one polyanion and polycation, which form nanoparticles via ion-ion interaction. The self-assembled polyelectrolytes can transport gold nanoparticles as CT contrast agents, or SPION or Gd(III) ions as MRI active ligands, and are labeled using a complexing agent with gallium as PET radiopharmacon. Furthermore, these dual modality PET/MRI and PET/CT contrast agents are labeled with targeting moieties to realize the tumorspecificity.
机译:已经开发了新型的基于纳米颗粒的双模态正电子发射断层扫描/磁共振成像(PET / MRI)和正电子发射断层扫描/计算机断层扫描(PET / CT)肿瘤特异性造影剂。新型造影剂的基础是具有PET,MRI和CT活性配体的基于生物聚合物的纳米颗粒。纳米颗粒包含至少一种聚阴离子和聚阳离子,其通过离子-离子相互作用形成纳米颗粒。自组装的聚电解质可以转运金纳米颗粒作为CT造影剂,或转运SPION或Gd(III)离子作为MRI活性配体,并使用与镓配合的配位剂作为PET放射性药物进行标记。此外,这些双重形式的PET / MRI和PET / CT造影剂均标有靶向部分,以实现肿瘤特异性。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号